Japanese drugmaker Eisai said in October it would add 200 sales jobs to help its partner Arena ($ARNA) with marketing of its weight-loss drug Belviq. Its R&D operations are not so lucky; the company is cutting them, with plans to eliminate 130 positions from its facility in Andover, MA, as well as other research centers around the world. FierceBiotech reports that it will move its small-molecule research work done in Andover to R&D facilities in Japan and India. Development work on large-molecule products that was being done in the facility north of Boston will go to its R&D facility in Exton, PA. Story | More